Project Grant R41CA306696
Award Date 8/18/26
Completion Date 7/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
East Haven, CT 06513, USA
Similar Awards
- The National Cancer Institute awarded Shasqi Inc. $3.330432 million on September 25, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and advance its Click Activated Protodrugs Against Cancer (CAPAC) platform for CEACAM5-targeted activation of chemotherapeutics via bioorthogonal click chemistry. Shasqi is developing a two-component system that uses bioorthogonal click chemistry to activate potent cytotoxic drugs precisely at tumor sites, thereby improving therapeutic...
- The National Institutes of Health National Cancer Institute awarded Oncotab, Inc. $1,130,587 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct Phase II SBIR research on a bispecific antibody T-cell engager (muCD3) combined with chemotherapy for pancreatic cancer treatment. Oncotab will advance muCD3 through preclinical studies designed to de-risk its path toward first-in-human trials and commercialization. The work includes evaluating muCD3 structural...
- The National Cancer Institute awarded Traverse Biotech II Inc. $399,896 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop TB-UA-1, a first-in-class antibody-drug conjugate targeting urokinase plasminogen activator receptor for treatment of pancreatic ductal adenocarcinoma. In Phase I, Traverse will construct and evaluate novel anti-uPAR ADC constructs using well-characterized human anti-uPAR antibodies (3C6 and 2G10) coupled with the company's proprietary...
- The National Cancer Institute awarded $400,000 to Dauntless Biotherapeutics, Inc. on August 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop CD155-targeted antibody-drug conjugates for metastatic and triple-negative breast cancer. The project advances therapeutic candidates that combine direct tumor cytotoxicity with restoration of anti-tumor immunity. CD155 is expressed in over 60% of breast cancers, including triple-negative, HER2-positive, and HER2-low...
- The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $606,950 to Pulse Biosciences, Inc., on September 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a minimally invasive pancreatic cancer treatment combining nanosecond electric pulses and immune system stimulants. The project aims to develop a two-component treatment for pancreatic ductal adenocarcinoma (PDAC) that employs endoscopic ultrasound guidance to deliver nanosecond...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Cancer Institute awarded Molecular Targeting Technologies, Inc. $637,529 on August 24, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop targeted radionuclide therapy for non-small cell lung cancer using Lu-177 EBRGD. The award funds research to evaluate in vivo tumor targeting, biodistribution, therapeutic efficacy, and normal tissue toxicity of 177Lu-DOTA-EB-RGD as a treatment for non-small cell lung cancer, which accounts for 80–85 percent...
- The National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, awarded $3.439 million to Mucommune LLC on September 16, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop in vivo-engineered B7-H3 CAR-T cells for pancreatic ductal adenocarcinoma immunotherapy. Mucommune is developing a novel platform that transduces circulating T-cells in vivo using a Nipah lentiviral vector with retargeted tropism, combined...
- The National Cancer Institute awarded Tiba Biotech LLC $399,300 on September 10, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop targeted delivery of enhanced self-amplifying RNA encoding tumor antigens to the spleen for cancer immunotherapy. Tiba Biotech will combine proprietary enhanced self-amplifying RNA (esRNA) technology with spleen-targeting biodegradable nanoparticles based on molecularly defined dendritic structures to deliver tumor antigen to...